Rocket


News + Filings
Key Docs
Ownership


All
All (ex-4s)
10-K
10-Q
8-K
3,4,5
Proxy
Prospectus
Other

VectivBio Holding AG Create: Alert

All | News | Filings
Date FiledTypeDescription
07/24/2023 EFFECT Form EFFECT - Notice of Effectiveness:
07/24/2023 EFFECT Form EFFECT - Notice of Effectiveness:
07/24/2023 EFFECT Form EFFECT - Notice of Effectiveness:
07/20/2023 POS AM Form POS AM - Post-Effective amendments for registration statement:
07/20/2023 POS AM Form POS AM - Post-Effective amendments for registration statement:
07/20/2023 POS AM Form POS AM - Post-Effective amendments for registration statement:
07/20/2023 S-8 POS Form S-8 POS - Securities to be offered to employees in employee benefit plans, post-effective amendments:
07/20/2023 S-8 POS Form S-8 POS - Securities to be offered to employees in employee benefit plans, post-effective amendments:
07/17/2023 6-K Form 6-K - Report of foreign issuer [Rules 13a-16 and 15d-16]:
Docs: "Articles of Association of VectivBio Holding AG, as amended",
"Articles of Association of VectivBio Holding AG, as amended"
07/10/2023 25 Form 25 - Notification of the removal from listing and registration of matured, redeemed or retired securities:
07/07/2023 SC 13D IRONWOOD PHARMACEUTICALS INC reports a 97.6% stake in VectivBio Holding AG
06/29/2023 SC 14D9/A Form SC 14D9/A - Solicitation, recommendation statements: [Amend]
06/29/2023 6-K Form 6-K - Report of foreign issuer [Rules 13a-16 and 15d-16]:
Docs: "6-K",
"Ironwood and VectivBio Announce the Completion of the Tender Offer for VectivBio Shares BOSTON and BASEL, Switzerland - June 29, 2023 - Ironwood Pharmaceuticals, Inc. , a GI-focused healthcare company, and VectivBio Holding AG , a global clinical-stage biopharmaceutical company pioneering novel, transformational treatments for severe rare gastrointestinal conditions, today announced the successful completion of the tender offer to purchase the outstanding ordinary shares of VectivBio for $17.00 per share in cash . The Depositary for the Tender Offer has advised Ironwood and VectivBio that at the end of the offering period, 59,287,753 Shares had been tendered and not withdrawn pursuant to the Tender Offer and it has received commitments to tender 2,007,310 additional Shares under the guaran..."
06/29/2023 SC TO-T/A Form SC TO-T/A - Tender offer statement by Third Party: [Amend]
06/16/2023 SC TO-T/A Form SC TO-T/A - Tender offer statement by Third Party: [Amend]
06/16/2023 SC 14D9/A Form SC 14D9/A - Solicitation, recommendation statements: [Amend]
06/16/2023 6-K Form 6-K - Report of foreign issuer [Rules 13a-16 and 15d-16]:
Docs: "6-K",
"Ironwood and VectivBio Announce Expiration of Hart-Scott-Rodino Waiting Period for Proposed Acquisition of VectivBio BOSTON and BASEL, Switzerland - June 16, 2023 - Ironwood Pharmaceuticals, Inc. , a GI-focused healthcare company, and VectivBio Holding AG , a global clinical-stage biopharmaceutical company pioneering novel, transformational treatments for severe rare gastrointestinal conditions, today announced that the waiting period under the Hart-Scott-Rodino Antitrust Improvements Act of 1976, as amended , in connection with Ironwood's pending acquisition of VectivBio, expired at 11:59 p.m., Eastern Time, on June 15, 2023. As previously announced on May 22, 2023, Ironwood commenced a tender offer to purchase all of VectivBio's outstanding ordinary shares for $17.00 per share in cash. T..."
06/05/2023 6-K Form 6-K - Report of foreign issuer [Rules 13a-16 and 15d-16]:
Docs: "Invitation to the Extraordinary General Meeting of Shareholders",
"Invitation to the Extraordinary General Meeting of Shareholders"
06/02/2023 6-K Form 6-K - Report of foreign issuer [Rules 13a-16 and 15d-16]:
Docs: "6-K",
"Articles of Association, as amended"
05/31/2023 SC 14D9 Form SC 14D9 - Solicitation, recommendation statements:
05/31/2023 SC TO-T Form SC TO-T - Tender offer statement by Third Party:
05/26/2023 SC 13G/A Novo Holdings A/S reports a 0% stake in VectivBio Holding AG
05/24/2023 SC 13D ORBIMED ADVISORS LLC reports a 7.7% stake in VectivBio Holding AG
05/23/2023 SC TO-C Form SC TO-C - Written communication relating to an issuer or third party:
05/10/2023 6-K Form 6-K - Report of foreign issuer [Rules 13a-16 and 15d-16]:
Docs: "6-K",
"Invitation to the 2023 Annual General Meeting",
"Twitter"
04/19/2023 20-F Form 20-F - Annual and transition report of foreign private issuers [Sections 13 or 15(d)]:
04/19/2023 6-K Quarterly results
04/06/2023 6-K Form 6-K - Report of foreign issuer [Rules 13a-16 and 15d-16]:
Docs: "Announcement of the Date of the Annual General Meeting of Shareholders",
"Announcement of the Date of the Annual General Meeting of Shareholders"
02/27/2023 EFFECT Form EFFECT - Notice of Effectiveness:
02/14/2023 SC 13G/A ORBIMED ADVISORS LLC reports a 10.7% stake in VectivBio Holding AG
02/14/2023 SC 13G/A Cormorant Asset Management, LP reports a 4% stake in VectivBio Holding AG
02/14/2023 SC 13G/A EVENTIDE ASSET MANAGEMENT, LLC reports a 5.4% stake in VectivBio Holding AG
02/14/2023 SC 13G/A Form SC 13G/A - Statement of acquisition of beneficial ownership by individuals: [Amend]
02/13/2023 SC 13G/A Form SC 13G/A - Statement of acquisition of beneficial ownership by individuals: [Amend]
  Next >>

Rocket Data Systems, Inc. © 2019 | Contact Us | Data Disclaimer | Terms of Use | Privacy